| 21.92 1.2 (5.79%) | 10-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 27.23  |
1-year : | 29.95 |
| Resists | First : | 23.31 |
Second : | 25.64 |
| Pivot price | 21.56 |
|||
| Supports | First : | 19.54 | Second : | 16.26 |
| MAs | MA(5) : | 21.02 |
MA(20) : | 22.06 |
| MA(100) : | 18.4 |
MA(250) : | 12.03 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 36.7 |
D(3) : | 29.5 |
| RSI | RSI(14): 50.6 |
|||
| 52-week | High : | 29.27 | Low : | 5.55 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NVCT ] has closed below upper band by 39.5%. Bollinger Bands are 53.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 22.01 - 22.12 | 22.12 - 22.21 |
| Low: | 20.79 - 20.91 | 20.91 - 21.01 |
| Close: | 21.73 - 21.93 | 21.93 - 22.09 |
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.
Thu, 24 Sep 2026
A brain tumor drug gets China’s breakthrough designation. Nuvectis is advancing NXP200 toward a U.S. filing in Q4. - stocktitan.net
Mon, 21 Sep 2026
Nuvectis Pharma (Nasdaq:NVCT) - Stock Analysis - Simply Wall Street
Fri, 18 Sep 2026
Nuvectis Pharma: Haisco Licensing Deal Revitalizes Biotech - But No Rush To Invest Today - Seeking Alpha
Tue, 04 Aug 2026
Nuvectis Reports $7.0 Million Q2 Net Loss After Pipeline Deals | NVCT Stock News - Quiver Quantitative
Wed, 29 Jul 2026
Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know - Yahoo Finance
Thu, 09 Jul 2026
The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 33 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 34.4 (%) |
| Held by Institutions | 33.5 (%) |
| Shares Short | 1,840 (K) |
| Shares Short P.Month | 1,510 (K) |
| EPS | -1.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.34 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -73.1 % |
| Return on Equity (ttm) | -214.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -16.61 |
| PEG Ratio | 0 |
| Price to Book value | 64.47 |
| Price to Sales | 0 |
| Price to Cash Flow | -36.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|